Patient-reported outcomes following primary total hip arthroplasty in Crowe type Ⅲ or Ⅳ developmental dysplasia are comparable to those in Crowe type Ⅰ: a case-control study of 96 hips with intermediate-term follow-up
Background: A few previous studies have investigated patient satisfaction after total hip arthroplasty (THA) according to the degree of pelvic deformity. This study compared patient-reported outcomes after primary THA for Crowe types Ⅲ, Ⅳ and I dysplasia.
Methods: This retrospective, single-center, single-surgeon case-control study included patients who underwent primary THA between 2008 and 2016. We sent postal questionnaires to 38 patients with Crowe type III and IV dysplasia. Among the questionnaire respondents, 23 patients, excluding those with a follow-up period of < 1 year, were enrolled as the H group. The control group included 46 patients with Crowe type I, matched for sex, age, body mass index and surgical approach. To investigate the influence of femoral shortening osteotomy, the H group was divided according to whether femoral shortening osteotomy was performed. Ten patients underwent THA with femoral shortening osteotomy (FO group), while 12 patients underwent THA without femoral shortening osteotomy (N-FO group). Patient demographics, mean follow-up period, surgical information, pre- and postoperative leg length discrepancy (LLD), and perioperative complications were investigated. Clinical evaluations were performed using the Japanese Orthopaedic Association (JOA) scores, 36-item short-form survey (SF-36), net promotor score (NPS), visual analogue scale (VAS), and questionnaires. The VAS and SF-36 scores were determined only at final follow-up.
Results: The H and control groups were not significantly different in the postoperative JOA scores and SF-36. In the H group, VAS at the final follow-up was significantly higher, and significantly more patients felt that postoperative rehabilitation was serious, expressing that they underwent THA for LLD correction. In addition, the VAS scores in the FO group was higher than those in the N-FO group. Postoperative LLD was significantly greater in the H group than in the control group. Each group had an NPS of >50.
Conclusion: The postoperative VAS score was higher in Crowe type Ⅲ and Ⅳ dysplasia than in Crowe type I dysplasia, but no significant differences were detected in the postoperative satisfaction, JOA score, and SF-36 score. These findings may help explain the effects of THA preoperatively to patients with Crowe type Ⅲ and Ⅳ dysplasia.
Level of Evidence: Therapeutic Level 3b
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Posted 21 May, 2020
On 11 May, 2020
On 10 May, 2020
On 10 May, 2020
On 05 May, 2020
On 30 Apr, 2020
Received 30 Apr, 2020
On 28 Apr, 2020
Received 28 Apr, 2020
Invitations sent on 27 Apr, 2020
On 27 Apr, 2020
Received 27 Apr, 2020
On 23 Apr, 2020
On 22 Apr, 2020
On 16 Apr, 2020
On 31 Mar, 2020
Received 20 Mar, 2020
On 10 Mar, 2020
Received 06 Mar, 2020
On 04 Mar, 2020
On 08 Jan, 2020
Received 08 Jan, 2020
Invitations sent on 02 Jan, 2020
On 20 Dec, 2019
On 17 Dec, 2019
On 17 Dec, 2019
On 04 Dec, 2019
Patient-reported outcomes following primary total hip arthroplasty in Crowe type Ⅲ or Ⅳ developmental dysplasia are comparable to those in Crowe type Ⅰ: a case-control study of 96 hips with intermediate-term follow-up
Posted 21 May, 2020
On 11 May, 2020
On 10 May, 2020
On 10 May, 2020
On 05 May, 2020
On 30 Apr, 2020
Received 30 Apr, 2020
On 28 Apr, 2020
Received 28 Apr, 2020
Invitations sent on 27 Apr, 2020
On 27 Apr, 2020
Received 27 Apr, 2020
On 23 Apr, 2020
On 22 Apr, 2020
On 16 Apr, 2020
On 31 Mar, 2020
Received 20 Mar, 2020
On 10 Mar, 2020
Received 06 Mar, 2020
On 04 Mar, 2020
On 08 Jan, 2020
Received 08 Jan, 2020
Invitations sent on 02 Jan, 2020
On 20 Dec, 2019
On 17 Dec, 2019
On 17 Dec, 2019
On 04 Dec, 2019
Background: A few previous studies have investigated patient satisfaction after total hip arthroplasty (THA) according to the degree of pelvic deformity. This study compared patient-reported outcomes after primary THA for Crowe types Ⅲ, Ⅳ and I dysplasia.
Methods: This retrospective, single-center, single-surgeon case-control study included patients who underwent primary THA between 2008 and 2016. We sent postal questionnaires to 38 patients with Crowe type III and IV dysplasia. Among the questionnaire respondents, 23 patients, excluding those with a follow-up period of < 1 year, were enrolled as the H group. The control group included 46 patients with Crowe type I, matched for sex, age, body mass index and surgical approach. To investigate the influence of femoral shortening osteotomy, the H group was divided according to whether femoral shortening osteotomy was performed. Ten patients underwent THA with femoral shortening osteotomy (FO group), while 12 patients underwent THA without femoral shortening osteotomy (N-FO group). Patient demographics, mean follow-up period, surgical information, pre- and postoperative leg length discrepancy (LLD), and perioperative complications were investigated. Clinical evaluations were performed using the Japanese Orthopaedic Association (JOA) scores, 36-item short-form survey (SF-36), net promotor score (NPS), visual analogue scale (VAS), and questionnaires. The VAS and SF-36 scores were determined only at final follow-up.
Results: The H and control groups were not significantly different in the postoperative JOA scores and SF-36. In the H group, VAS at the final follow-up was significantly higher, and significantly more patients felt that postoperative rehabilitation was serious, expressing that they underwent THA for LLD correction. In addition, the VAS scores in the FO group was higher than those in the N-FO group. Postoperative LLD was significantly greater in the H group than in the control group. Each group had an NPS of >50.
Conclusion: The postoperative VAS score was higher in Crowe type Ⅲ and Ⅳ dysplasia than in Crowe type I dysplasia, but no significant differences were detected in the postoperative satisfaction, JOA score, and SF-36 score. These findings may help explain the effects of THA preoperatively to patients with Crowe type Ⅲ and Ⅳ dysplasia.
Level of Evidence: Therapeutic Level 3b
Figure 1
Figure 2
Figure 3